Shares are trading at $17.05 which is well above $15.24, the stock’s 50 day moving average and significantly above the 200 day moving average of $14.67. The 50 day moving average was up by +11.86% whereas the 200 day average was up by +16.19%. Trading volume for Concert Pharmaceuticals, Inc. was 136K on Tuesday. Trading volume was down 43.88% under the stocks average daily volume.
Traders are more bullish on Concert Pharmaceuticals, Inc. as implied by the motion in short interest. The stock saw a fall in short interest of -8.29% as of October 13, 2017 from the last reporting period. Short interest fell 41,725 over that period. With short interest at 461,577 and short average daily volume at 98,121, the short-interest ratio is 5.0 and the percentage of shorted shares is 0.02% as of October 13.
The following firms have recently changed their position in CNCE. As of quarter end Meeder Asset Management Inc had sold a total of 129 shares trimming its position 36.1%. The value of the investment in Concert Pharmaceuticals, Inc. decreased from $5,000 to $3,000 decreasing 40.0% for the reporting period. Rockefeller Financial Services Inc cut its position by shedding 756 shares a decrease of 7.3%. Rockefeller Financial Services Inc now holds 9,533 shares with a value of $141,000. The value of the position overall is down by 2.1%.
Ingalls & Snyder LLC grew its investment by buying 153,062 shares an increase of 14.5% as of 09/30/2017. Ingalls & Snyder LLC owns 1,209,062 shares worth $17,834,000. The total value of its holdings increased 21.1%. Simplex Trading, LLC augmented its ownership by buying 10,378 shares an increase of 221.8% from 06/30/2017 to 09/30/2017. Simplex Trading, LLC claims 15,058 shares valued at $222,000. The total value of its holdings increased 241.5%.
H.C. Wainwright added CNCE to its research portfolio giving it an initial rating of “Buy”. Equity analyst Mizuho added the stock to its research portfolio with an initial rating of “Buy”.
As of the latest earnings report the EPS was $-2.22 and is expected to be $-2.18 for the current year with 22,687,000 shares presently outstanding. Next quarter’s EPS is forecasted at $-0.73 with next year’s EPS anticipated to be $-2.44.
Concert Pharmaceuticals, Inc., launched on April 12, 2006, is a clinical-stage biopharmaceutical company. The Company is involved in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Business’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386..